Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.
Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.
X4 Pharmaceuticals announced a $125 million capital infusion through the sale of a Priority Review Voucher and a drawdown from an existing loan facility. This extends their cash runway into late 2025, excluding expected commercial sales from XOLREMDI™, the first drug approved for patients with WHIM syndrome.
X4 Pharmaceuticals reported financial results for the first quarter of 2024, with $81.6 million in cash. The FDA approved XOLREMDI for WHIM syndrome, and a Phase 3 trial data was published. Interim data from a Phase 2 trial in chronic neutropenia is expected in June 2024. X4 plans to initiate a Phase 3 trial for autoimmune and chronic neutropenia. The company expects EMA approval for mavorixafor in late 2024/early 2025.
Despite promising developments, X4 reported an increase in R&D and SG&A expenses, leading to a net loss of $51.8 million for the first quarter of 2024.
X4 Pharmaceuticals announced the issuance of inducement awards to new employees under the 2019 Inducement Plan, consisting of options to purchase 605,349 shares of X4's common stock. The options have a ten-year term, with an exercise price of $1.12 per share, and will vest over a four-year period, subject to continued employment.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will report first-quarter 2024 financial results on May 7, 2024, and host a conference call and webcast. The company focuses on rare immune system diseases, aiming to enhance patient lives.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.